European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Euro Surveill. 2009 Nov 19;14(46):19412.
During the 2007-08 influenza season, high levels of oseltamivir resistance were detected among influenza A(H1N1) viruses ina number of European countries. We used surveillance data to describe influenza A(H1N1) cases for whom antiviral resistance testing was performed. We pooled data from national studies to identify possible risk factors for infection with a resistant virus and to ascertain whether such infections led to influenza illness of different severity. Information on demographic and clinical variables was obtained from patients or their physicians. Odds ratios for infection with an oseltamivir resistant virus and relative risks for developing certain clinical outcomes were computed and adjusted through multivariable analysis. Overall, 727 (24.3%) of 2,992 tested influenza A(H1N1) viruses from 22 of 30 European countries were oseltamivir-resistant. Levels of resistance ranged from 1% in Italy to 67% in Norway. Five countries provided detailed case-based data on 373 oseltamivir resistant and 796 susceptible cases. By multivariable analysis, none of the analysed factors was significantly associated with an increased risk of infection with anoseltamivir-resistant virus. Similarly, infection with an oseltamivir-resistant virus was not significantly associated with a different risk of pneumonia, hospitalisation or any clinical complication. The large-scale emergence of oseltamivir-resistant viruses in Europe calls for a review of guidelines for influenza treatment.
在 2007-08 年流感季节,一些欧洲国家的甲型 H1N1 流感病毒中检测到高水平的奥司他韦耐药性。我们使用监测数据描述了进行抗病毒耐药性检测的甲型 H1N1 流感病例。我们汇集了来自国家研究的数据,以确定感染耐药病毒的可能危险因素,并确定此类感染是否导致不同严重程度的流感疾病。患者或其医生提供了有关人口统计学和临床变量的信息。通过多变量分析计算了感染奥司他韦耐药病毒的优势比和发生某些临床结局的相对风险。总体而言,在来自 30 个欧洲国家中的 22 个国家的 2,992 份甲型 H1N1 流感病毒检测样本中,有 727 份(24.3%)为奥司他韦耐药病毒。耐药水平从意大利的 1%到挪威的 67%不等。有 5 个国家提供了有关 373 例奥司他韦耐药和 796 例敏感病例的详细基于病例的数据。通过多变量分析,没有分析因素与感染奥司他韦耐药病毒的风险增加显著相关。同样,感染奥司他韦耐药病毒与肺炎、住院或任何临床并发症的风险增加没有显著相关性。奥司他韦耐药病毒在欧洲的大规模出现需要重新审查流感治疗指南。